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Abstract
Introduction The high-affinity receptor for IgG Fcγ/CD64 is
critical for the development of lupus nephritis (LN). Cross-linking
Fc receptor on recruited monocytes by IgG-containing immune
complexes is a key step in immune-complex-mediated nephritis
in systemic lupus erythematosus (SLE). The goal of this study
was to determine whether expression of Fc receptor (FcγR) I on
circulating monocytes is associated with systemic inflammation
and renal disease in SLE patients.
Methods We studied 205 SLE patients (132 with LN and 73
without LN) along with 74 healthy control individuals. Surface
expression of CD14 (monocytes), FcγRI/CD64, FcγRII/CD32,
and FcγRIII/CD16 was evaluated by flow cytometry. Monocyte
function was assessed by determining the migratory capacity
and the ability to produce CCL2 (monocyte chemotractic
protein 1). High-sensitivity C-reactive protein, C3 and C4 were
measured by nephelometry.
Results There was little difference in the expression of FcγRIII/
CD16 or FcγRIII/CD32 on circulating monocytes between
patients with SLE and control individuals. In contrast, FcγRI/
CD64 expression was significantly higher in SLE patients and
even higher in patients with LN. FcγRI/CD64 expression was
positively associated with serum creatinine and indicators of
systemic inflammation. Monocytes from patients with high
FcγRI/CD64 expression also exhibited increased chemotaxis
and capacity to produce monocyte chemotractic protein 1.
Conclusions Increased FcγRI/CD64 expression on circulating
monocytes parallels systemic inflammation and renal disease in
SLE patients. We propose that circulating monocytes activated
by immune complexes and/or proinflammatory mediators
upregulate surface expression of FcγRI/CD64 in SLE. The
enhanced chemotactic and inflammatory potential of the
activated monocytes may participate in a vicious cycle of
immune cell recruitment and renal injury in SLE.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune dis-
ease characterized by the production of autoantibodies
against a wide array of self-antigens [1]. Formation of immune
complexes (ICs) between these autoantibodies and the target
antigens has been linked to the development of lupus nephritis
(LN) [2,3]. Deposition of ICs in the kidneys activates mono-
cyte/macrophages by interacting with Fc receptor (FcγR) I and
FcγRIII, initiating an inflammatory cascade of cytokines and
chemokines. The release of proinflammatory mediators such
as monocyte chemotractic protein 1 (MCP-1 (CCL2)), macro-
phage inflammatory protein 1 (CCL3) and fractalkine
(CX3CL1) recruits monocyte/macrophages and other immune
effector cells, culminating in tissue damage [4,5].
Three classes of FcγRs are expressed on circulating human
monocytes. FcγRI/CD64 is a high-affinity receptor constitu-
tively expressed at substantial levels by monocytes [6]. Mono-
cytes also express high levels of FcγRII/CD32, a low-affinity
receptor for ICs with two functionally distinct isoforms. In con-Page 1 of 13
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plexed IgG, is present on only about 10% to 15% of
circulating monocytes [7]. FcγRI, FcγRIIa and FcγRIII are acti-
vating Fc receptors bearing intracytoplasmic tyrosine-based
activation motifs that trigger monocyte activation upon recep-
tor aggregation. FcγRIIb, on the other hand, contains an immu-
noreceptor tyrosine-based inhibitory motif and functions as an
inhibitory Fc receptor upon interacting with ICs [8].
The balance of activating and inhibitory FcγR determines the
magnitude of the cellular response in monocytes. Enhanced
expression of activating FcγRs or decreased expression of the
inhibitory FcγR can lower the activation threshold, leading to
the production of inflammatory cytokines that may promote LN
[9]. Conversely, NZB/W F1 mice deficient in FcγRI/III are pro-
tected from LN despite developing extensive IC deposits [10].
As in Wegener's granulomatosis [11] and rheumatoid arthritis
[12], circulating monocytes in SLE are activated and exhibit
increased surface expression of FcγRI/CD64 [13]. Whether
this increase in activating FcγR on monocytes is related to
development of LN, however, is unknown.
To investigate the possible role of activating FcγR in human
LN, we examined the expression of FcγRI/CD64, FcγRIII/
CD16 and FcγRII/CD32 on circulating monocytes from SLE
patients, and the relationship of FcγR expression levels to renal
involvement and chemokine production.
Materials and methods
Study population
The present study was approved by the University of Florida
Institutional Review Board, and all subjects provided written
informed consent prior to participation. SLE patients met at
least four of the revised 1982 American College of Rheuma-
tology criteria [14]. Peripheral blood was collected from 205
patients and 74 healthy control individuals. In the patient
group, 132 participants had either biopsy-proven or labora-
tory-proven LN and 73 had no evidence of LN. At each visit a
medication history and key laboratory parameters were col-
lected. Disease activity was assessed using the Systemic
Lupus Erythematosus Disease Activity Index [15]. Detailed
demographics, clinical characteristics, medication usage and
laboratory measurements for all groups are presented in Table
1.
Cell surface staining
Antibodies were obtained from BD Pharmingen (San Diego,
CA, USA) unless indicated otherwise. Heparinized whole
blood (100 μl) was stained with PerCP-conjugated anti-CD14
(clone MΦ P9), fluorescein isothiocyanate-conjugated anti-
CD16 (clone 3G8), allophycocyanin-conjugated anti-CD32
(clone FLI8.26), anti-HLA-DR (clone LN3), anti-CD62L (clone
DREG56; eBioscience, San Diego, CA, USA), phycoerythrin-
conjugated anti-CD64 (clone X54-5/7.1.1), and anti-CD16
(clone 3G8) for 30 minutes in the dark. Following lysis of eryth-
rocytes, cells were washed with PBS/1% BSA/0.01% NaN3
and were fixed in 2% paraformaldehyde PBS. Cells (105) were
analyzed using a FACSCalibur flow cytometer and CellQuest
software (Becton Dickinson, Mountain View, CA, USA).
Gates were set around monocytes based on their forward/
sideward light scatter pattern and CD14 expression. Surface
marker expression levels were expressed as the geometrical
mean fluorescence intensity on monocytes. Since not all
CD14 monocytes express CD16, CD32, CD62L and HLA-
DR, expression was also expressed as the percentage of pos-
itive monocytes. Data analysis was performed using FCS
Express 2.0 (De Novo Software, Thornhill, ON, Canada).
Analysis of chemokine production
Heparinized whole blood was diluted 1:1 with DMEM (Medi-
atech, Inc., Herndon, VA, USA) containing 10% fetal bovine
serum (Mediatech, Inc.), and was stimulated with lipopolysac-
charide (LPS) (500 ng/ml, from Escherichia coli; Sigma
Chemical Company, St Louis, MO, USA) or C-reactive protein
(CRP) (50 ng/ml, purified from human serum, endotoxin-free;
Calbiochem, La Jolla, CA, USA) in the presence of the protein
transport inhibitor GolgiStop™ (BD Pharmingen). In all cases,
cells were incubated at 37°C in a 5% CO2 atmosphere for 4
hours. The dose of LPS and CRP and the length of incubation
were optimized for chemokine production in preliminary exper-
iments. Immediately after incubation, 100 μl aliquots of cells
were stained with appropriate combinations of monoclonal
antibodies for 30 minutes at 22°C in the dark. After incubation,
2 ml PharMlyse (BD Pharmingen) was added to lyse erythro-
cytes. After washing, cells were fixed and permeabilized with
200 μl Cytofix/Cytoperm solution (BD Pharmingen) for 20
minutes at 4°C. After two washes with Perm/Wash solution
(BD Pharmingen), cells were resuspended in 100 μl Perm/
Wash solution containing 1.5 μg/μl phycoerythrin-conjugated
anti-MCP-1 clone (5D3-F7; BD Pharmingen) or the same con-
centration of phycoerythrin-conjugated mouse IgG1 as an iso-
type control. After incubating at 4°C for 30 minutes in the dark,
cells were washed and analyzed by flow cytometry.
Chemotaxis assay
Peripheral blood mononuclear cells isolated from SLE patients
and from healthy control individuals using Ficoll-Hypaque den-
sity gradient centrifugation were washed once and resus-
pended in DMEM containing 0.5% fetal bovine serum at a
concentration of 107 cells/ml. Medium containing MCP-1 (25
ng/ml; Research Diagnostics Inc., Flanders, NJ, USA) or
medium alone as a control were added to the lower chambers
of a 24-well Costar Transwell plate (Corning Inc. Corning, NY,
USA). The cell suspension (100 μl) was added to the upper
chamber, which was separated from the lower chamber by a
polycarbonate membrane (8.0 μm pores). After incubation for
3 hours at 37°C, cells in the lower chamber were collected,
stained with anti-CD14, anti-CD16, and anti-HLA-DR, and
analyzed by flow cytometry. Results are presented as a migra-Page 2 of 13
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migrated toward MCP-1 by the number of cells that migrated
to medium alone.
Measurement of C-reactive protein and complement
High-sensitivity C-reactive protein, C3 and C4 assays were
performed using a BN ProSpec® Nephelometer (Dade
Behring, Deerfield, IL, USA) as described elsewhere [16].
In vitro stimulation of healthy donor peripheral blood 
mononuclear cells
Peripheral blood mononuclear cells from healthy control indi-
viduals were plated on 24-well plates (106 cells/well) in com-
plete medium (DMEM supplemented with 10% fetal bovine
serum, 20 mM L-glutamine, 100 IU/ml penicillin, and 100 μg/
ml streptomycin). All cytokines were from BD Bioscience
unless indicated otherwise. Cells were incubated for 19 hours
at 37°C in the presence of recombinant human IFNα (4 ng/ml;
Table 1
Demographics, laboratory characteristics and clinical characteristics of participants
Control individuals (n = 74) SLE patients without LN (n = 73) SLE patients with LN (n = 132)
Demographics
Female (%) 93 93 90
Mean age (years) 38 37 35
Race (%)
African-American 37 31 43
Caucasian 32 49* 32†
Others 31 20 25
Disease duration (years) - 9.0 ± 0.8 10.3 ± 0.8
American College of Rheumatology 
criteria count
- 6.0 ± 0.2 6.4 ± 0.2
Serum markers
C3 (mg/dl) 125.1 ± 5.3 100.0 ± 3.7* 92.6 ± 5.0*
C4 (mg/dl) 24.7 ± 2.1 17.0 ± 1.1 19.4 ± 1.5
High-sensitivity C-reactive protein (mg/dl) 1.4 (1.1 to 4.4) 5.5 (4.1 to 7.0)* 5.8 (4.0 to 7.5)*
SLE manifestationa (%)
Central nervous system - 21 14
Skin - 65 53
Joint - 87 68
Serositis - 31 35
Anti-dsDNA - 45 78††
Anti-Smith - 40 57†
Anti-phospholipid - 44 51
Medication usageb (%) -
Prednisone - 45 55
Mean dose (mg/day) - 12.5 17.5
Antimalarials - 80 72
Cytotoxics - 28 68††
Statins - 11 28†
Angiotensin-converting enzyme inhibitors - 46 65†
aPresence of specific manifestations at any point during the course of disease. bMedication usage at the time of this study. *P < 0.05 for systemic 
lupus erythematosus (SLE) patients with or without lupus nephritis (LN) versus healthy controls. †P < 0.05 or ††P < 0.001 for SLE patients with LN 
versus SLE patients without LN.Page 3 of 13
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ng/ml), IL-6 (4 ng/ml), IL-8 (4 ng/ml), IL-12 (4 ng/ml), or CRP
(50 ng/ml; Calbiochem). Flow cytometry was performed
immediately after incubation. In some experiments, dexameth-
asone (10-5 to 10-3 M) was added to the culture 3 hours prior
to the addition of cytokines.
Statistical analysis
Differences between disease groups and normal control indi-
viduals were evaluated using Student's two-tailed t test unless
the data were not normally distributed, in which case the
Mann–Whitney U test was used. Correlation coefficients were
calculated using Spearman's rank correlation. Data are pre-
sented as the mean ± standard error of the mean. Analyses
were performed using Prism software, version 4.0 (GraphPad
Software, San Diego, CA, USA). For all analyses, P < 0.05
was considered significant.
Results
We assessed the surface expression of FcγRs on monocytes
from SLE patients with or without LN and from healthy control
individuals. Demographics and clinical/laboratory data are
summarized in Table 1. There was no difference in the percent-
age of circulating CD14+ monocytes between SLE patients
with or without LN and normal control individuals (Table 2).
Absolute monocyte counts, however, were significantly
decreased in SLE patients with/without LN when compared
with normal control individuals (268 ± 29 cells/μl and 254 ±
39 cells/μl, respectively, versus 357 ± 32 cells/μl; both P <
0.005, Student's t test).
Increased FcγRI/CD64 expression on SLE monocytes
In healthy control individuals, nearly all peripheral blood mono-
cytes displayed surface expression of FcγRI/CD64 and
FcγRII/CD32. Only 9.3 ± 0.7% of circulating monocytes, how-
ever, expressed FcγRIII/CD16 (Figure 1a, top and Table 2).
Although circulating monocytes from SLE patients also uni-
formly expressed FcγRI/CD64 (Figure 1a, bottom), quantifica-
tion of FcγRI/CD64 expression showed a significantly higher
mean fluorescence intensity in SLE patients compared with
healthy control individuals (521 ± 21 versus 319 ± 22; P <
0.001, Student's t test). The expression was even higher in
patients with nephritis compared with those without nephritis
(567 ± 28 versus 449 ± 31; P < 0.001, Student's t test) (Fig-
ure 1b and Table 2).
In contrast, CD32 expression was similar on CD14+ mono-
cytes from SLE patients versus normal healthy control individ-
uals (Figure 1c and Table 2). While the frequencies and
absolute numbers of CD16+CD14+ monocytes were similar
between SLE patients and control individuals, the intensity of
CD16 staining was increased slightly in SLE patients with or
without LN (12 ± 0.4 and 13 ± 0.6, respectively, versus con-
trol individuals 10 ± 0.6; both P < 0.01, Student's t test) (Fig-
Table 2
Comparison of cell surface marker expression by CD14+ monocytes
Control individuals SLE patients without LN SLE patients with LN
CD14+ cells
Percentagea 4.3 ± 0.4 3.9 ± 0.3 4.0 ± 0.2
Mean fluorescence intensity 596.8 ± 42.9 604.8 ± 29.9 605.3 ± 18.7
Absolute number (cell/μl) 357.2 ± 31.5 254.1 ± 38.5* 268.3 ± 29.4*
FcγRIII/CD16
Percentagea 9.3 ± 0.7 11.0 ± 0.6* 10.8 ± 0.6
Mean fluorescence intensity 10.2 ± 0.6 13.2 ± 0.6** 12.5 ± 0.4*
Absolute number (cell/μl) 23.3 ± 4.1 53.6 ± 10.0 78.9 ± 15.7
FcγRII/CD32
Percentagea 87.5 ± 2.9 85.9 ± 2.3 81.8 ± 2.9
Mean fluorescence intensity 71.6 ± 8.3 64.4 ± 7.5 68.4 ± 5.9
Absolute number (cell/μl) 266.7 ± 49.2 249.1 ± 114.5 238.2 ± 100.9
FcγRI/CD64
Percentagea 99.9 ± 0.03 99.9 ± 0.02 99.9 ± 0.03
Mean fluorescence intensity 319.1 ± 22.2 449.2 ± 30.5** 567.0 ± 28.1**††
Absolute number (cell/μl) 352.8 ± 0.11 252.8 ± 0.05* 268.0 ± 0.08*
*P < 0.05 or **P < 0.001 for systemic lupus erythematosus (SLE) patients with or without lupus nephritis (LN) versus healthy control individuals. 
†P < 0.05 or ††P < 0.001 for SLE patients with LN versus SLE patients without LN.Page 4 of 13
(page number not for citation purposes)
Available online http://arthritis-research.com/content/11/1/R6
Page 5 of 13
(page number not for citation purposes)
Figure 1
Expression of Fc receptors in healthy control individuals versus systemic lupus erythematosus patientsression of Fc receptors in healthy control in ividuals versus systemic lupus erythematosus patients. (a) Representative scattergrams of 
surface expression of FcγRI/CD64, FcγRII/CD32 and FcγRIII/CD16 on CD14+ monocytes from a healthy control individual (top) and a patient with 
systemic lupus erythematosus (SLE) (bottom). CD14+ monocytes were gated based on their forward/sideward scatter. (b-d) Expression of FcγRI/
CD64, FcγRII/CD32 and FcγRIII/CD16, respectively (mean fluorescence intensity (MFI)) on SLE versus control monocytes. SLE patients with and 
without lupus nephritis (LN) are analyzed separately. Differences between groups were compared by Student's t test. (e) Comparison of FcγRI/
CD64 expression (MFI) on monocytes from SLE patients without LN or with biopsy-proven World Health Organization class II, class III/IV, or class V 
LN. *P < 0.05 compared with SLE patients without LN (Student's t test).
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DR and CD62L, markers related to monocyte activation, but
found no significant differences between the groups (data not
shown).
To further evaluate the relationship between FcγR expression
and LN, we analyzed the expression of FcγRs on monocytes in
79 patients who had undergone renal biopsy (class II, n = 7;
class III/IV, n = 43; and class V, n = 29). The presence of class
III/IV or class V LN, but not of class II LN, was associated with
increased expression of FcγRI/CD64 compared with SLE
patients who did not have LN (Figure 1e). In contrast, the
expression of FcγRII and FcγRIII was similar among the differ-
ent classes of LN (data not shown).
Increased FcγRI/CD64 expression is associated with 
impaired renal function
Since FcγRI/CD64 expression on monocytes was greater in
SLE patients with LN compared with SLE patients without LN,
we investigated its relationship with individual markers of renal
involvement. Increased expression of FcγRI/CD64 on mono-
cytes correlated positively with elevated creatinine (r2 = 0.27,
P < 0.001; Spearman's correlation) (Figure 2a, left) and blood
urea nitrogen levels (r2 = 0.12, P = 0.001; Spearman's corre-
lation) (Figure 2a, middle), as well as with the degree of pro-
teinuria (microalbumin/creatinine ratio, r2 = 0.10, P < 0.001;
Spearman's correlation) (Figure 2a, right).
Increased levels of FcγRI/CD64 expression are 
associated with ongoing inflammation
We next examined the relationship of FcγRI/CD64 expression
with measures of systemic inflammation such as high-sensitiv-
ity CRP and complement C3 [17]. In patients with SLE, the
expression of FcγRI/CD64 on monocytes was positively corre-
lated with elevated serum levels of high-sensitivity CRP (r2 =
0.14, P < 0.0001; Spearman's correlation) (Figure 2b). FcγRI/
CD64 expression showed an inverse relationship with serum
C3 (r2 = 0.07, P < 0.0001; Spearman's correlation) (Figure
2c) but not with C4 (r2 = 0.01, P = 0.14) (data not shown).
Increased FcγRI/CD64 expression was also associated with
anti-dsDNA autoantibodies (534.1 ± 21.4 versus 426.5 ±
21.0 mean fluorescence intensity units, P = 0.0005) (Figure
2d). Increased FcγRI/CD64 surface expression on monocytes
was therefore associated with impaired renal function, anti-
dsDNA autoantibody production, C3 consumption, and ongo-
ing inflammation in SLE patients.
FcγRI/CD6hi monocytes have an activated phenotype
Monocyte migration to the kidneys and the subsequent
release of inflammatory mediators are thought to be critical
steps initiating renal damage [18,19]. We evaluated the migra-
tory capacity of circulating monocytes from SLE patients using
an in vitro transwell assay, and found that monocytes with ele-
vated FcγRI/CD64 expression exhibited increased migration
toward the chemokine MCP-1 (r2 = 0.09, P = 0.005; Spear-
man's correlation) (Figure 3a).
As monocyte-derived proinflammatory cytokines and chemok-
ines such as MCP-1 regulate immune cell infiltration and play
an important role in organ damage in SLE [20], we examined
the ability of CD64+ monocytes to produce MCP-1. After LPS
stimulation, monocytes with high FcγRI/CD64 expression pro-
duced higher levels of the chemokine than CD64- monocytes,
as measured by intracellular staining (r2 = 0.09, P < 0.001;
Spearman's correlation) (Figure 3b).
Since the binding of CRP to FcγRI/CD64 and FcγRIIa/CD32a
can lead to increased inflammatory cytokine production [21-
23], we stimulated monocytes from SLE patients with CRP
(50 ng/ml) and analyzed the MCP-1 production. CRP and LPS
elicited similar levels of intracellular MCP-1 staining (compare
Figure 3b and Figure 3c). Consistent with the results with LPS
stimulation, high FcγRI/CD64 surface expression was associ-
ated with increased intracellular MCP-1 production in
response to CRP (r2 = 0.26, P = 0.03; Spearman's correla-
tion) (Figure 3c). Monocytes with elevated surface expression
of FcγRI/CD64 therefore displayed a more activated pheno-
type in terms of migratory properties and MCP-1 production in
response to either LPS or CRP.
Medication effects on FcγRI/CD64 expression
Corticosteroids potently downmodulate certain inflammatory
markers on circulating monocytes [24]. Since about one-half
of our SLE patients were treated with corticosteroids (Table
1), we asked whether the levels of FcγRI/CD64 expression by
monocytes were affected by treatment. When analyzed as a
group, patients treated with conventional doses of prednisone
(< 40 mg/day) showed no difference in FcγRI/CD64 expres-
sion compared with those patients not treated with corticos-
teroids (Figure 4a). There also was no apparent effect of
antimalarial, cytotoxic or statin therapy on the expression of
FcγRs (Figure 4a). Stratifying patients based on the pred-
nisone dose revealed that a daily dosage ≥ 40 mg was asso-
ciated with decreased FcγRI/CD64 expression on monocytes
(Figure 4b). A similar trend (not statistically significant) was
seen at a dose of 20 to 30 mg/day. This effect was not seen
at lower dosages (Figure 4b). Patients treated with ≥ 40 mg/
day prednisone tended to display lower serum levels of C3
(67.6 ± 8.5 versus 93.7 ± 3.4 mg/dl; P < 0.05) and higher lev-
els of blood urea nitrogen (36.9 ± 9.0 versus 15.6 ± 0.8 ng/
dl; P < 0.05) compared with their counterparts given lower
doses, consistent with higher disease activity (data not
shown). There was no difference in Systemic Lupus Erythema-
tosus Disease Activity Index scores, American College of
Rheumatology criteria counts, serum creatinine, high-sensitiv-
ity CRP levels, or microalbumin/creatinine ratios between the
groups (data not shown).Page 6 of 13
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Figure 2
FcγRI/CD64 expression on monocytes correlates with renal disease, C-reactive protein, and complement C3 levelspre sion on monocytes correlates with renal disease, C-reactive protein, and complement C3 levels. (a) FcγRI/CD64 expres-
sion levels on circulating monocytes from systemic lupus erythematosus (SLE) patients (both lupus nephritis (LN) and non-LN patients) correlated 
with increased serum creatinine (left) and blood urea nitrogen (BUN) (middle), as well as with proteinuria (microalbumin/creatinine ratio) (right). MFI, 
mean fluorescence intensity. Expression of FcγRI/CD64 correlated (b) positively with serum high-sensitivity C-reactive protein (HsCRP) levels and 
(c) negatively with serum C3 levels (Spearman's correlation). (d) Comparison of FcγRI/CD64 expression in SLE patients positive or negative for anti-
dsDNA autoantibodies (Student's t test).
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Several studies have shown that the expression of FcγRI/
CD64 can be influenced by different cytokines in pathogenic
circumstances. Dysregulation of proinflammatory cytokine pro-
duction has also been well documented in SLE. To examine
potential inducers of FcγRI/CD64 upregulation, we stimulated
peripheral blood mononuclear cells from healthy control indi-
viduals with a panel of cytokines. Overnight incubation with
IFNα, IFNγ, and IL-12 significantly increased FcγRI/CD64
expression on monocytes, whereas IL-6, IL-8, IL-10, TNFα,
and CRP treatment did not (Figure 5a). Similar results were
obtained when the experiment was performed using cultured
THP-1 cells (data not shown).
Curiously, while the addition of dexamethasone to whole blood
did not alter the steady-state levels of FcγRI/CD64 expression
on monocytes in vitro (Figure 5b), high concentrations of dex-
amethasone (≥ 10-4 M) inhibited the upregulation of FcγR1/
CD64 expression induced by IFNγ, IFNα and IL-12 (Figure
5c). This effect was not seen with lower concentrations of dex-
amethasone.
Discussion
In mouse models of SLE, monocytes/macrophages bearing
activating Fc receptors are pivotal to the development of IC-
mediated glomerulonephritis [25,26]. There is indirect evi-
dence that the same may be true of human lupus [27,28],
although the relationship between activating FcγR expression
and the pathogenesis of human LN is less clear than in the
mouse. In the present study, we examined FcγR expression in
more than 200 SLE patients. The levels of FcγRI/CD64
expression on circulating monocytes were significantly ele-
vated in SLE patients, especially in those with LN. Increased
monocyte FcγRI/CD64 expression also was associated with
markers of impaired renal function impairment and with a
greater ability to migrate and secrete the chemokine MCP-1.
The proinflammatory role of activating FcγR in LN is evident in
mice deficient in FcγRI/III, which are protected from the devel-
opment of renal disease despite the presence of glomerular IC
deposits [10]. A recent study showed that the expression of
FcγRI/III by monocytes was both necessary and sufficient to
trigger nephritis in NZB/W F1 mice [26]. In contrast, the inhib-
itory FcγRIIb suppresses inflammation and spontaneous acti-
vation of autoreactive lymphocytes and autoantibody
production in mice [26,29].
In human SLE, several groups have shown the abnormal
upregulation of activating Fcγ receptors on monocytes
[13,30]. One relatively small study, however, found no signifi-
cant difference in FcγRI/CD64 or FcγRIII/CD16 expression on
SLE monocytes compared with healthy controls [31]. About
two-thirds of the patients studied here had elevated levels of
monocyte surface CD64 in the present study, a discrepancy
that may be due to the relatively small number of subjects stud-
ied previously. Consistent with the observations of others
[13,28], our data show that the activating receptor FcγRIII/
CD16 also is upregulated in SLE patients compared with
Figure 3
FcγRI/CD64hi monocytes have an activated phenotypei onocytes have an activated phenotype. (a) Correlation between FcγRI/CD64 expression levels and monocyte migration toward 
monocyte chemotractic protein 1 (MCP-1) (transwell assay, systemic lupus erythematosus (SLE) patients). (b) Correlation of elevated FcγRI/CD64 
expression on monocytes with an increased capacity to produce MCP-1, as measured by intracellular staining of CD14+ monocytes 4 hours after 
lipopolysaccharide (LPS) stimulation. MFI, mean fluorescence intensity. (c) Correlation of FcγRI/CD64 expression with levels of MCP-1 production 
by monocytes following C-reactive protein (CRP) stimulation for 4 hours.Page 8 of 13
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data support the idea that activating FcγRs play a crucial role
in IC-mediated organ damage in SLE.
Although NZB/W F1 mice deficient in activating FcγRs are
protected from renal disease, the relative contributions of the
individual activating FcγRs have not been studied further. Our
data show that although both FcγRIII/CD16 and FcγRI/CD64
expression were elevated, increased FcγRIII/CD16 expression
was not associated with LN, suggesting that activation via
FcγRI/CD64 may be more significant to the pathogenesis of
human LN. Moreover, we found no difference in the surface
expression of FcγRII/CD32 on monocytes between the SLE
patients and healthy control individuals, although interpreta-
tion of this finding is limited by the inability of the anti-CD32
antibody to distinguish the activating FcγRIIa and inhibitory
FcγRIIb. Expression of the inhibitory FcγRIIb in peripheral
blood mononuclear cells from SLE patients has been recently
studied using specific antibodies [32]. While low expression
levels were found on B-lymphocyte subsets, FcγRIIb/CD32b
expression was not impaired on monocytes from SLE patients.
The importance of FcγRs in the pathogenesis of SLE is further
illustrated by extensive polymorphism studies involving FcγRII/
Figure 4
Effect of medications and cytokines on FcγRI/CD64 expression by circulating monocytest f edications and cytokines on FcγRI/CD64 expression by circulating monocytes. (a) Comparison of FcγRI/CD64 expression on 
monocytes between systemic lupus erythematosus (SLE) patients receiving or not receiving prednisone, antimalarials, cytotoxic drugs, or statins. 
MFI, mean fluorescence intensity. (b) Relationship between daily corticosteroid dose and monocyte FcγRI/CD64 expression in SLE patients. *P < 
0.05 compared with SLE patients not receiving steroid treatment.Page 9 of 13
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including FcγRIIa-131R, FcγRIIIa-176F, and FcγRIIIb-NA2 –
have been associated with lupus susceptibility [33,34]. Impor-
tantly, some of them cause functional alterations of the inhibi-
tory receptor [35,36] while others are associated with
reduced surface expression of FcγRIIb on both memory and
plasma B lymphocytes [37]. To our knowledge, however, pol-
ymorphisms involving FcγRI/CD64 have not been linked to
SLE.
The markedly elevated expression of FcγRI/CD64 among SLE
patients with LN (Figure 1b) may serve as a surrogate marker
of renal disease that correlates with both established meas-
ures of renal dysfunction (increased serum creatinine, blood
urea nitrogen, and proteinuria) and inflammation (elevated
serum CRP, C3 deficiency). Monocyte FcγRI/CD64 expres-
sion, however, did not correlate with overall disease activity as
assessed by the Systemic Lupus Erythematosus Disease
Activity Index (data not shown). This was not due to medica-
tion use, since FcγRI/CD64 levels on circulating monocytes
were unaffected by treatment with prednisone at doses < 40
Figure 5
Effect of cytokines and dexamethasone on FcγRI/CD64 expression in vitrot f cytokines an  dexamethasone on FcγRI/CD64 expression in vitro. (a) Direct effects of cytokines and C-reactive protein (CRP) on 
FcγRI/CD64 expression on circulating monocytes. Peripheral blood mononuclear cells from healthy subjects were cultured with recombinant IFNα 
(4 ng/ml), IFNγ (2 ng/ml), IL-4 (4 ng/ml), IL-6 (4 ng/ml), IL-8 (4 ng/ml), IL-12 (4 ng/ml) or CRP (50 ng/ml) for 19 hours in vitro. FcγRI/CD64 expres-
sion (mean fluorescence intensity (MFI)) was analyzed by flow cytometry. Values represent the mean ± standard error of the mean (SEM) from five 
independent experiments. *P < 0.001 compared with medium alone. (b) Effect of dexamethasone on monocyte FcγRI/CD64 expression in vitro. Val-
ues represent the mean ± SEM from three independent experiments. (c) Effect of dexamethasone on the upregulation of FcγRI/CD64 by IFNα, IFNγ, 
and IL-12. Values represent the mean ± SEM from two independent experiments.Page 10 of 13
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trast, higher doses of prednisone (≥ 40 mg/day) or dexameth-
asone treatment in vitro reduced FcγRI/CD64 expression,
possibly due to direct effects on proinflammatory cytokine pro-
duction [38,39] or to the generation of a subset of anti-inflam-
matory monocytes that secrete IL-10 [40,41].
Our in vitro data suggest that IL-12, IFNγ, and IFNα are poten-
tial inducers of FcγRI/CD64 expression in SLE. Interestingly,
excess production of all three of these cytokines promotes LN
in mice [42-44]. In human LN, increased levels of IFNγ, IL-12
and IFNα/β are found in the kidney [45,46]. Dysregulation of
IFNα production is also associated with renal involvement
[47]. Our data are consistent with the possibility that the over-
production of one or more of these cytokines promotes LN by
enhancing the recruitment of proinflammatory (CD64+) mono-
cytes/macrophages to the renal glomerulus. Although there
was a highly significant correlation between FcγRI/CD64
expression and several markers of renal involvement or inflam-
mation (Figure 2), the r2 values were in some cases relatively
low. This indicated the existence of additional variables, at
present undefined, affecting FcγRI/CD64 expression. Eluci-
dating the variables that affect FcγRI/CD64 expression, per-
haps including serum levels of the cytokines examined in our
in vitro studies, will require further study.
FcγRI/CD64 plays a role in phagocytosis, cytolysis, degranu-
lation, and induction of inflammatory cytokines. Additionally,
FcγRI-deficient mice display defective peritoneal monocyte
infiltration in response to ICs [48]. Consistent with these stud-
ies, our data demonstrated that circulating human monocytes
from patients with upregulated FcγRI/CD64 expression exhib-
ited increased migratory capacity and MCP-1 production in
response to LPS or CRP stimulation. Monocyte/macrophage
infiltration is important in promoting mesangial hypercellularity
and the development of glomerulosclerosis in both human and
animal models [49,50]. Additionally, the number of infiltrating
monocytes/macrophages is associated with more severe
renal injury and poor prognosis in LN [50,51].
As seen in animal models [10,26,52], monocytes expressing
FcγRI/CD64 may be important to the pathogenesis of IC-
mediated nephritis in SLE. Elevated production of IFNα and
IFNγ in SLE may induce the expression of FcγRI/CD64 mono-
cytes and facilitate the infiltration of these cells to the sites of
IC deposition in the kidney [48]. Since IFNα and IFNγ also
stimulate the production of monocyte attractants such as
MCP-1, the presence of these cytokines in the kidney also may
promote the influx of monocytes. In turn, signal transduction
downstream of FcγRI/CD64 leads to monocyte activation and
further production of inflammatory cytokines and chemokines.
These events could culminate in a vicious cycle of renal inflam-
mation and monocyte infiltration, ultimately leading to perma-
nent tissue damage.
Conclusion
Our study demonstrates that elevated surface expression of
FcγRI/CD64 is associated with ongoing systemic inflamma-
tion and renal disease in lupus patients. We propose that
upregulation of FcγRI/CD64 expression on circulating mono-
cytes may be a useful surrogate marker of monocyte activation
in SLE.
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